News
List of company announcements and press releases.
Click here for announcements regarding managers transactions.
Click here for news in Danish.
April 16, 2024 | Company Announcements
Resolutions of the Annual General Meeting 2024 of Bavarian Nordic A/SApril 02, 2024 | Press Releases
Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.March 21, 2024 | Company Announcements
Bavarian Nordic A/S – Notice Convening Annual General MeetingMarch 13, 2024 | Press Releases
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in SwitzerlandMarch 06, 2024 | Company Announcements
Bavarian Nordic Publishes Annual Report 2023February 23, 2024 | Company Announcements
Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines AgencyFebruary 21, 2024 | Company Announcements
Bavarian Nordic delivered record financial results in 2023December 13, 2023 | Company Announcements
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic November 30, 2023 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseNovember 16, 2023 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2023October 25, 2023 | Company Announcements
Bavarian Nordic’s Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at RiskSeptember 13, 2023 | Press Releases
Bavarian Nordic Awarded Another Contract to Supply Smallpox Vaccines for EU Strategic ReserveSeptember 04, 2023 | Company Announcements
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchSeptember 01, 2023 | Company Announcements
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchAugust 31, 2023 | Company Announcements
Bavarian Nordic Provides Update on COVID-19 Booster Vaccine ProgramAugust 23, 2023 | Company Announcements
Bavarian Nordic Announces First Half 2023 ResultsAugust 06, 2023 | Company Announcements
Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents August 03, 2023 | Company Announcements
Bavarian Nordic Receives USD 120 Million Contract for the Manufacturing of Smallpox and Mpox Vaccine from the U.S. GovernmentJuly 22, 2023 | Company Announcements
Bavarian Nordic Provides Update on RSV Vaccine Program June 27, 2023 | Company Announcements
Bavarian Nordic Reports Phase 3 Topline Results for its COVID-19 Booster Vaccine CandidateJune 23, 2023 | Company Announcements
Bavarian Nordic to Supply Smallpox Vaccines for EU Strategic ReserveJune 20, 2023 | Company Announcements
Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age June 16, 2023 | Company Announcements
Bavarian Nordic Reports 12-Month Durability Data from a Phase 2 Clinical Trial of its COVID-19 Vaccine CandidateJune 12, 2023 | Company Announcements
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchMay 23, 2023 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise